Therapeutic strategies to overcome taxane resistance in cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Therapeutic strategies to overcome taxane resistance in cancer

Published:2021-03 Issue: Volume:55 Page:100754
ISSN:1368-7646
Container-title:Drug Resistance Updates
language:en
Short-container-title:Drug Resistance Updates

Author:

Das Tuyelee,Anand Uttpal,Pandey Swaroop Kumar,Ashby Charles R.,Assaraf Yehuda G.,Chen Zhe-Sheng,Dey Abhijit

Funder

Presidency University

Publisher

Elsevier BV

Subject

Pharmacology (medical),Infectious Diseases,Cancer Research,Pharmacology,Oncology

Reference378 articles.

1. A role for hypoxia and hypoxia-inducible transcription factors in tumor physiology;Acker;J. Mol. Med.,2002

2. Contemporary formulations for drug delivery of anticancer bioactive compounds;Ackova;Recent Pat. Anticancer Drug Discov.,2019

3. A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance;Advani;Clin. Canc. Res.,2001

4. Control of microtubule organization and dynamics: two ends in the limelight;Akhmanova;Nat. Rev. Mol. Cell Biol.,2015

5. What is nuclear factor kappa B (NF-κB) doing in and to the mitochondrion?;Albensi;Front. Cell Dev. Biol.,2019

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Programmed nanocarrier loaded with paclitaxel and dual-siRNA to reverse chemoresistance by synergistic therapy;International Journal of Biological Macromolecules;2024-03

2. Inhibition of NF-κB signaling unveils novel strategies to overcome drug resistance in cancers;Drug Resistance Updates;2024-03

3. Ultrasound-enhanced nano catalyst with ferroptosis-apoptosis combined anticancer strategy for metastatic uveal melanoma;Biomaterials;2024-03

4. Methylation of GPRC5A promotes liver metastasis and docetaxel resistance through activating mTOR signaling pathway in triple negative breast cancer;Drug Resistance Updates;2024-02

5. mTOR inhibitor introduce disitamab vedotin (RC48-ADC) rechallenge microtubule-chemotherapy resistance in HER2-low MBC patients with PI3K mutation;Frontiers in Oncology;2024-01-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3